Advertisement
Advertisement
EIKN
Eikon Therapeutics, Inc. Common Stock
6.13
USDSponsored
+0.26
+4.43%
Nov 10, 15:59 UTC -5
Closed
After-Market
6.13
0.00
0.00%
Eikon Therapeutics, Inc. Common Stock (EIKN) Earnings
EIKN Earnings Reports
Positive Surprise Ratio
EIKN beat 0 of 2 last estimates.
0%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Eikon Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 13, 2026, EIKN reported earnings of -1.63 USD per share (EPS) for Q2 26, missing the estimate of -1.61 USD, resulting in a -0.82% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +6.97% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Eikon Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Eikon Therapeutics, Inc. Common Stock reported EPS of -$1.63, missing estimates by -0.82%, and revenue of $0.00, 0% as expectations.
How did the market react to Eikon Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 6.97%, changed from $10.33 before the earnings release to $11.05 the day after.
When is Eikon Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Eikon Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Eikon Therapeutics, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.